Full Press Release Details
Ultragenyx Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Update.
RARE
Ultragenyx Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Update
Key Takeaway: Ultragenyx Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Update
Price reaction · baseline $45.66 (2024-02-14 close) · hit after-hours · clean, no other RARE news in the window
day 0 close
+1.3%
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+43%
120-day peak, hindsight
Typical move
2.9%
average across 6 past catalysts
Cash runway
~13 mo
Low dilution risk
Lead asset
BPS804
Phase 2 · Hypophosphatasia